Global Patent Index - EP 1016715 A1

EP 1016715 A1 2000-07-05 - Oligonucleotides having a conserved G4 core sequence

Title (en)

Oligonucleotides having a conserved G4 core sequence

Title (de)

Oligonukleotide mit einer konservierten G4-Kernsequenz

Title (fr)

Oligonucléotides possédant une séquence centrale G4 conservée

Publication

EP 1016715 A1 (EN)

Application

EP 99203835 A

Priority

  • EP 93922788 A
  • US 95418592 A

Abstract (en)

Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

IPC 1-7 (main, further and additional classification)

C12N 15/11; A61K 31/7125

IPC 8 full level (invention and additional information)

C12N 15/09 (2006.01); A01N 63/00 (2006.01); A61K 31/70 (2006.01); A61P 31/12 (2006.01); A61P 31/16 (2006.01); A61P 35/00 (2006.01); C07H 21/00 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); C12N 15/115 (2010.01); C12N 15/117 (2010.01); C12P 19/34 (2006.01); C12Q 1/68 (2006.01); C12Q 1/70 (2006.01); A61K 38/00 (2006.01)

CPC (invention and additional information)

A61K 31/70 (2013.01); C07H 21/00 (2013.01); C12N 15/1133 (2013.01); C12N 15/1137 (2013.01); C12N 15/115 (2013.01); C12N 15/117 (2013.01); C12Q 1/701 (2013.01); C12Y 207/07049 (2013.01); C12Y 301/01004 (2013.01); A61K 38/00 (2013.01); C12N 2310/151 (2013.01); C12N 2310/18 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01)

Combination set (CPC)

C12N 2310/321 + C12N 2310/3521

Citation (search report)

  • [Y] WO 9015813 A1 19901227 - CENTRE NAT RECH SCIENT [FR]
  • [XY] AGRAWAL S ET AL: "OLIGODEOXYNUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHOROTHIOATES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, 1 October 1988 (1988-10-01), pages 7079 - 7083, XP000574956, ISSN: 0027-8424
  • [Y] ZAHLER A M ET AL: "INHIBITION OF TELOMERASE BY G-QUARTET DNA STRUCTURES", NATURE, vol. 350, 25 April 1991 (1991-04-25), pages 718 - 720, XP002913087, ISSN: 0028-0836
  • [A] KIM J ET AL: "TETRAMERIZATION OF AN RNA OLIGONUCLEOTIDE CONTAINING A GGGG SEQUENCE", NATURE, vol. 351, 23 May 1991 (1991-05-23), pages 331 - 332, XP002068652, ISSN: 0028-0836
  • [A] CHEONG C ET AL: "SOLUTION STRUCTURE OF AN UNUSUALLY STABLE RNA TETRAPLEX CONTAINING G- AND U-QUARTET STRUCTURES", BIOCHEMISTRY, vol. 31, no. 36, 15 September 1992 (1992-09-15), pages 8406 - 8414, XP002041658, ISSN: 0006-2960
  • [PX] ECKER D ET AL: "RATIONAL SCREENING OF OLIGONUCLEOTIDE COMBINATORIAL LIBRARIES FOR DRUG DISCOVERY", NUCLEIC ACIDS RESEARCH, vol. 21, no. 8, 25 April 1993 (1993-04-25), pages 1853 - 1856, XP002015215, ISSN: 0305-1048
  • [T] WYATT J R ET AL: "COMBINATORIALLY SELECTED GUANOSINE-QUARTET STRUCTURE IS A POTENT INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE-MEDIATED CELL FUSION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, February 1994 (1994-02-01), pages 1356 - 1360, XP002068456, ISSN: 0027-8424

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9408053 A1 19940414; AT 222290 T 20020815; AU 5167393 A 19940426; AU 668604 B2 19960509; BR 1100614 A 20000411; CA 2145664 A1 19940414; CA 2145664 C 20020820; DE 69332206 D1 20020919; DE 69332206 T2 20030528; EP 0672193 A1 19950920; EP 0672193 A4 19951122; EP 0672193 B1 20020814; EP 1016715 A1 20000705; FI 951467 A0 19950328; FI 951467 A 19950328; HU 9500911 D0 19950529; HU T70965 A 19951128; IL 107150 D0 19931228; JP 2818031 B2 19981030; JP H08500738 A 19960130; NO 951191 A 19950328; NO 951191 D0 19950328; NZ 256787 A 19970424; NZ 314251 A 19990528; US 2007015723 A1 20070118; US 2007270363 A1 20071122; US 2011124715 A1 20110526; US 5523389 A 19960604; US 5952490 A 19990914

INPADOC legal status


2006-07-05 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20060104

2005-06-29 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: ISIS PHARMACEUTICALS, INC.

2005-01-05 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20041117

2001-03-21 [AKX] PAYMENT OF DESIGNATION FEES

- Free text: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

2001-02-07 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20001212

2000-07-05 [AC] DIVISIONAL APPLICATION (ART. 76) OF:

- Document: EP 672193

2000-07-05 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE